Author: Yun Hu1, Yi Dan Xie1, Xiaozhen Xu2, Yanyan Liu1, Chengrui Zhang1, Huiru Wang3
Affiliation: <sup>1</sup> School of Nursing, Shanghai Jiao Tong University, Shanghai, China. <sup>2</sup> School of Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, Shanghai, China. <sup>3</sup> Department of Physical Education; Institution of Health Yangtze River Delta, Shanghai Jiaotong University, Shanghai, China.
Conference/Journal: Physiother Theory Pract
Date published: 2022 Oct 19
Other: Special Notes: doi: 10.1080/09593985.2022.2135977. , Word Count: 205
This study aimed to identify facilitators and barriers to adherence to a Baduanjin program experienced by breast cancer survivors (BCSs) during chemotherapy.
Semi-structured interviews with 10 BCSs in an interprofessional BaDuanJin program were conducted to understand their experiences, including the facilitators and barriers concerning exercise. Content analysis was performed following the behaviour change wheel (BCW).
The following five domains emerged from the analysis: 1) Capacity: Recovery of upper limb function, symptom relief, and emotional release are facilitators; periodic treatment and related symptoms and negative emotions are barriers; 2) Motivation: Reflection on health, positive belief, and weight control are facilitators; a doubtful attitude is a barrier; 3) Opportunity: Recuperating at home is a facilitator; 4) Intervention: Facilitators include simple and gentle exercise at home, comprehensive tutoring by an interprofessional team, treating exercise as a task occurring at a fixed time, and peer support. The hindrances are work and home duties prior to exercise and a lack of group activities; and 5) Policy: Social media promotion and less support from physicians are facilitators and barriers, respectively.
Identifying facilitators and barriers leads to improved support from health professionals, which is required to provide effective strategies to increase adherence to BaDuanJin exercise.
Keywords: BaDuanJin; barriers; breast cancer; chemotherapy; facilitators.
PMID: 36259288 DOI: 10.1080/09593985.2022.2135977